Identification and targeting of selective vulnerability rendered by tamoxifen resistance

BACKGROUND: The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast cancer, the acquired resistance to TMX anti-estrogen therapy is the main hurdle...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Singh, Madhurendra, Zhou, Xiaolei, Chen, Xinsong, Santos, Gema Sanz, Peuget, Sylvain, Cheng, Qing, Rihani, Ali, Arnér, Elias S. J., Hartman, Johan, Selivanova, Galina
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7388523/
https://ncbi.nlm.nih.gov/pubmed/32727562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01315-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars